Acetylcholine in irritable bowel syndrome pathogenesis and the role of cholineblockers
Abstract
The aim of review. To demonstrate value of disorders of cholinergic innervation in pathogenesis of irritable bowel syndrome (IBS).
Original positions. The important place in regulation of gastro-intestinal tract functions belongs not only to M-, but also to N-receptors localized in enteral plexus ganglions and on presynaptic endings of cholinergic motor neurones. Acetylcholine is the universal mediator which is intimately interacts with other mediators regulating intestinal functions. The role of disorders of cholinergic innervation in pathogenesis of IBS is actively investigated by now. Experimental data allow to assume, that «subclinical inflammation» within intestinal wall at IBS, disturbances of peristaltic activity and hyperalgesia, are related to altered response of immune and smooth-muscle cells to acetylcholine stimulation.
Conclusion. Acetylcholine represents the major mediator regulating motor and secretory function of intestine. Change of acetylcholine metabolism of has immediate value in pathogenesis of IBS. The agents, influencing cholinergic receptors, are one of basic resources of modern pharmaceutical therapy of irritable bowel syndrome.
About the Author
Yu. O. Shulpekova
ГОУ ВПО «1-й Московский государственный медицинский университет им. И.М. Сеченова Росздрава»
Russian Federation
Russian Federation
References
1. Арутюнов А.Г., Бурков С.Г. Синдром раздраженного кишечника с позиции практикующего врача // Рус. мед. журн. – 2006. – Т. 13, № 27.
2. Баранская Е.К. Боль в животе: клинический подход к больному и алгоритм лечения. Место спазмолитической терапии в лечении абдоминальной боли // Фарматека.– 2005. – № 14. – С. 35–38.
3. Белоусова Е.А. Абдоминальная боль в практике терапевта // Врач. – 2002. – № 2. – С. 16–20.
4. Ивашкин В.Т., Баранская Е.К. Синдром раздраженного кишечника. Избранные лекции по гастроэнтерологии. – М.: МЕДпресс, 2001. – C. 54–82.
5. Макарчук П.А., Халиф И.Л., Михайлова Т.Д., Головенка О.В. Динамика показателей висцеральной чувствительности у больных с синдромом раздраженного кишечника при лечении спазмолитиками // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2008.– Т. 18, № 1. – С. 45–51.
6. Махов В.М., Ромасенко Л.В., Турко Т.В.Коморбидность дисфункциональных расстройств органов пищеварения // Болезни органов пищеварения. – 2007. – Т. 9, № 2. – С. 37–42.
7. Румянцев В.Г. Синдром раздраженного кишечника: путь к Римским критериям III // Фарматека. – 2008.– № 10. – С. 16–23.
8. Синдром раздраженного кишечника: Учебное пособие / Под ред. И.В. Маева. – М., 2004.
9. Шептулин А.А. Современные представления о синдроме раздраженного кишечника // Рус. мед. журн. – 2001. – № 12. – С. 538–544.
10. Akiho H., Deng Y., Blennerhassett P. et al. Mechanisms underlying the maintenance of muscle hypercontractility in a model of post infective gut dysfunction // Gastroenterology. – 2005. – Vol. 129, N 1. – P. 131–141.
11. Benabdallah H., Messaoudi D., Gharzouli K. The spontaneous mechanical activity of the circular smooth muscle of the rabbit colon in vitro // Pharmacol. Res. – 2008. – Vol. 57, N 2. – P. 132–141.
12. Callahan M.J. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds // J. Clin. Gastroenterol. – 2002. – Vol. 35, N 1 (suppl.). – P. 58–67.
13. Choudhury B.K., Shi X.Z., Sarna S.K. Gene plasticity in colonic circular smooth muscle cells underlies motility dysfunction in a model of postinfective IBS // Am. J. Physiol. Gastrointest. Liver Physiol. – 2009. – Vol. 296, N 3. – P. 632–642.
14. Crentsil V. Will corticosteroids and other antiinflammatory agents be effective for diarrhea-predominant irritable bowel syndrome? // Med. Hypotheses. – 2005. – Vol. 65, N 1. – P. 97–102.
15. De Schepper H.U., De Winter B.Y., Seerden T.C. et al. The role of tachykinins in circular muscle contractility of the murine ileum: a functional investigation // Auton Neurosci. – 2006. – Vol. 126–127. – P. 273–276.
16. Dinan T.G., Clarke G., Quigley E.M. et al. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors // Am. J. Gastroenterol. – 2008.
17. – Vol. 103, N 10. – P. 2570–2576.
18. Gershon M.D. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome
19. // J. Clin. Gastroenterol. – 2005. – Vol. 39, N 5 (suppl. 3). – P. 184–193.
20. Gibbs R.B. Estrogen therapy and cognition: a review of the cholinergic hypothesis // Endocr. Rev. – 2010.
21. – Vol. 31, N 2. – P. 224–253.
22. Hunt R.H., Tougas G. Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments // Best Pract. Res. Clin. Gastroenterol. – 2002. – Vol. 16, N 6. – P. 869–883.
23. Ishii M., Kurachi Y. Muscarinic acetylcholine receptors // Curr. Pharmaceut. Des. – 2006. – Vol. 12, N 28. – P. 3573–3581.
24. Jailwala J., Imperiale T., Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systemic review of randomized, controlled trials // Ann. Intern. Med. – 2000. – Vol. 133. – P. 136–147.
25. Kobayashi S., Ikeda K., Suzuki M. et al. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo // Jpn. J. Pharmacol. – 2001. – Vol. 86, N 3. – P. 281–288.
26. Leng Y.X., Wei Y.Y., Chen H. et al. Alteration of cholinergic and peptidergic neurotransmitters in rat ileum induced by acute stress following transient intestinal infection is mast cell dependent // Chin. Med. J. (Engl). 2010. – Vol. 123, N 2. – P. 227–33.
27. Mandl P., Kiss J.P. Role of presynaptic nicotinic acetylcholine receptors in the regulation of gastrointestinal motility // Brain Res. Bull. – 2007. – Vol. 72, N 4–6.– P. 194–200.
28. Miftahof R., Akhmadeev N.R. Neurochemical bases of visceral nociception: mathematical model // J. Theor. Biol. – 2007. – Vol. 249, N 2. – P. 343–360.
29. Mitch C.H., Brown T.J., Bymaster F.P. et al.Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome // J. Med. Chem.– 1997. – Vol. 40, N 4. – P. 538–546.
30. Miyoshi A. A multi-centre, double-blind evaluation against placebo of the therapeutic effect of hyoscine-N-butylbromide in patients with abdominal pain // Pharmatherapeutica.– 1976. – Vol. 1, N 1. – P. 46–51.
31. Motzer S.A., Jarrett M., Heitkemper M.M., Tsuji J. Natural killer cell function and psychological distress in women with and without irritable bowel syndrome // Biol. Res. Nurs. – 2002. – Vol. 4, N 1. – P. 31–42.
32. Mueller-Lissner S., Tytgat G.N., Paulo L.G. et al. Placebo and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain // Aliment. Pharmacol. Ther. – 2006. – Vol. 23. – P. 1741–1748.
33. Ohman L., Isaksson S., Lundaren A. et al. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome // Clin. Gastroenterol. Hepatol. – 2005. – Vol. 3, N 10. – P. 980–986.
34. Peretto I., Petrillo P., Imbimbo B.P. Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists // Med. Res. Rev. – 2009. – Vol. 29, N 6. – P. 867–902.
35. Sarna S.K. Enteric descending and afferent neural signaling stimulated by giant migrating contractions: essential contributing factors to visceral pain // Am. J. Physiol. Gastrointest. Liver Physiol. – 2007. – Vol. 292, N 2. – P. 572–581.
36. Sarna S.K. Tachykinins and in vivo gut motility // Dig. Dis. Sci. – 1999. – Vol. 44, N 8 (suppl.). – P. 114–118.
37. Simmen U., Kelber O., Okpanyi S.N. et al. Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors // Phytomedicine. – 2006. – Vol. 13 (suppl. 5). – P. 51–55.
38. Tytgat G. Hyoscine butylbromide. A review of its use in the treatment of abdominal cramping and pain // Drugs. – 2007. – Vol. 67, N 9. – P. 1343–1357.
39. Ueno N., Inui A., Satoh Y. The effect of mosapride citrate on constipation in patients with diabetes // Diabetes Res. Clin. Pract. – 2010. – Vol. 87, N 1. – P. 27–32.
40. Van der Veek P.P., van den Bera M. et al. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome // Clin. Gastroenterol. Hepatol. – 2005. – Vol. 3, N 10. – P. 980–986.
41. Weiser T., Just S. Hyoscine butylbromide potently blocks human nicotinic acetylcholine receptors in SHSY5Y cells // Neurosci. Lett. – 2009. – Vol. 450, N 3.
42. – P. 258–261.
Review
For citations:
Shulpekova Yu.O. Acetylcholine in irritable bowel syndrome pathogenesis and the role of cholineblockers. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(1):26-31. (In Russ.)
Views:
114
Email this article 
